Shanghai Medicilon Inc - Asset Resilience Ratio
Shanghai Medicilon Inc (688202) has an Asset Resilience Ratio of 10.17% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Shanghai Medicilon Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Shanghai Medicilon Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Shanghai Medicilon Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Medicilon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Shanghai Medicilon Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥281.42 Million | 10.17% |
| Total Liquid Assets | CN¥281.42 Million | 10.17% |
Asset Resilience Insights
- Moderate Liquidity: Shanghai Medicilon Inc has 10.17% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Medicilon Inc Industry Peers by Asset Resilience Ratio
Compare Shanghai Medicilon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Shanghai Medicilon Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Medicilon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.33% | CN¥113.41 Million ≈ $16.59 Million |
CN¥2.62 Billion ≈ $383.69 Million |
-4.93pp |
| 2024-12-31 | 9.25% | CN¥261.22 Million ≈ $38.23 Million |
CN¥2.82 Billion ≈ $413.13 Million |
-6.62pp |
| 2023-12-31 | 15.87% | CN¥518.23 Million ≈ $75.83 Million |
CN¥3.27 Billion ≈ $477.90 Million |
+10.29pp |
| 2021-12-31 | 5.58% | CN¥100.00 Million ≈ $14.63 Million |
CN¥1.79 Billion ≈ $262.46 Million |
-- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more